Arkolith/Insider Trading/XENE/Form 4

Mortimer Ian

PRESIDENT & CEO, DirectorXenon Pharmaceuticals Inc. (XENE) · full profile →Form 4 · filed Mar 13, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$404K
Net Open-Market Flow
-$404K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 13, 2026Sell(S)7K$55.23$404K20K
Mar 12, 2026Option exercise(M)13K——27K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 12, 2026Option exercise(M)13K—$038K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-106724) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML